2A Pharma

AAVLP Vaccines and Therapeutics

News

Press Release: 2A Pharma AB Raises SEK 27 Million and Signs Exclusive Worldwide License Agreement

16 January 2017

2A Pharma AB Press Release 2017-01-16

Article about 2A Pharma in MedWatch

16 January 2017

The following article was published in Danish pharma industry publication MedWatch on 16 January 2017.

http://medwatch.dk/secure/Medicinal___Biotek/article9288529.ece

 

Exclusive Worldwide License Agreement

20 December 2016

Medigene AG today announced that it has granted an exclusive, worldwide license for the development and commercialization of its preclinical stage adeno-associated virus like particles (AAVLPs) technology to 2A Pharma AB.

Read the full press release here.

First Financing Round Closed

19 December 2016

2A Pharma AB today closed its first financing round, raising SEK 27 million from private angel investors. This new capital will enable us to take our first project, the AAVLP-HPV vaccine, through to the end of phase I clinical studies. We are grateful for our investors’ support and trust.

2A Pharma AB is a Reality

12 December 2016

2A Pharma AB is a Reality

2A Pharma AB is a Reality2A Pharma AB was incorporated in Sweden on 12 December 2016. Søren Nielsen, CEO: “This marks the formal beginning of a new exciting venture and the team is very excited about the journey ahead.”

Contact

2A Pharma AB
Södergatan 3
211 34 Malmö
Sweden

E-mail info@2apharma.com

Registration Number: 559090-2788
VAT: SE559090278801

About Us

2A Pharma is a Swedish/Danish biopharmaceutical company focused on discovering, developing and commercialising novel, cost effective vaccines and therapeutics based on the AAVLP platform. The story of the technology behind our company started in 2005 when John Nieland, then Head of Immunology at … [Read More]